系统性硬化症介入研究十年:试验注册库的系统性映射
该系统映射检索了国际临床试验注册平台2007年9月以来针对系统性硬化症(SSc)的介入性临床试验,共纳入198项研究,其中122项为随机对照试验(RCT,62%)。研究发现多数试验规模小、周期短、以安慰剂对照为主,主要评估药物治疗,皮肤增厚、雷诺现象/指端溃疡和间质性肺病是研究最多的并发症。
要点
- 198项研究中RCT占62%,多数为单国、药企资助的安慰剂对照小样本试验。
- RCT中位入组或计划入组40例,仅17%的RCT计划或已入组超过100例。
- 研究最多的并发症为皮肤增厚(26%)、雷诺现象/指端溃疡(24%)和间质性肺病(14%)。
核心结论
- SSc介入研究以小型、短期、安慰剂对照试验为主,尤其集中于药物治疗,部分患者需求仍被忽视。
研究设计与样本
- 检索国际临床试验注册平台2007年9月以来的介入性临床试验记录,由两名评价者按预设标准筛选,共纳入198项研究。
主要发现
- 198项研究中122项为RCT(62%),87项(30%)在欧洲开展,165项(83%)为单国研究,81项(41%)由企业资助。
- 多数试验评估药物治疗(75%),其中非生物制剂占57%;RCT多为双臂(82%)、安慰剂对照(71%)。
- 仅29%至50%的RCT评估主要结局的时间点被认为充分;14%的研究排除了65岁以上患者。
- 研究最多的并发症为皮肤增厚(26%)、雷诺现象/指端溃疡(24%)和间质性肺病(14%)。
临床怎么用
- 解读SSc试验证据时需注意多数研究样本量小、以安慰剂对照为主,外推至广泛患者群体时应谨慎。
局限性
- 原文未报告检索时限的具体截止日期及未注册试验的遗漏情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide a comprehensive overview of interventional clinical trials registered in international databases and planned and conducted within the last 10 years in patients with systemic sclerosis (SSc). METHODS: We searched the International Clinical Trials Registry Platform for all records on interventional clinical trials targeting patients with SSc performed since September 2007. Two reviewers selected studies according to the prespecified eligibility criteria. Information on start date, country of origin, funding sources, phase of development, study design, (planned) sample size, enrollment status, outcomes, disease complication, and treatments investigated were retrieved and summarized. RESULTS: Among the 198 eligible studies identified (122 randomized controlled trials [RCTs; 62%]), 87 (30%) were conducted in Europe, 165 (83%) in a single country, and 81 (41%) were industry-funded. The majority of trials investigated pharmacologic treatments (75%), mostly nonbiotherapies (57%). RCTs were mostly 2-arm (82%) placebo-controlled (71%) studies with a median number of patients enrolled or planned to be enrolled of 40 (interquartile range 25-77 [range 10-586]). Twenty-one RCTs (17%) planned to enroll or enrolled >100 patients. Time to assess the primary outcome was found to be adequate in 29% to 50% of RCTs retrieved. Patients age >65 years were excluded in 14% of studies. SSc complications more frequently investigated in overall studies were skin thickness (26%), Raynaud's phenomenon/digital ulcers (24%), and interstitial lung disease (14%). CONCLUSION: The SSc research landscape is dominated by small, short, and mainly placebo-controlled trials, especially investigating pharmacologic treatments. Some patients' needs continue to be neglected.
引用
- Iudici M, Bafeta A, Atal I, et al. Ten Years of Interventional Research in Systemic Sclerosis: A Systematic Mapping of Trial Registries. Arthritis Care Res (Hoboken). 2019. PMID: 30474928. doi:10.1002/acr.23817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。